- NASDAQ: SNDL gained 0.36% during Tuesday’s trading session.
- Stifel analysts still believe Valens is a risk-adjusted opportunity for investors.
- Tilray Medical receives approval for clinical trials for its CBD products in Australia.
NASDAQ: SNDL rebounded from a tough sell off on Monday as the announced acquisition sank in with investors of the cannabis company. On Tuesday, shares of SNDL edged higher by 0.36% and closed the session at a price of $2.77. Stocks were flat on Tuesday, although all three major indices closed lower for the second straight day. Investors still seem to be pessimistic ahead of the annual Jackson Hole Symposium that begins on Thursday. Overall, the Dow Jones lost 154 basis points, the S&P 500 dropped by 0.22%, and the NASDAQ traded flat for the session.
Stay up to speed with hot stocks' news!
While Sundial and the Valens Company (TSE: VLNS) both tumbled on Monday following the merger announcement, some analysts have a different spin on the deal. Analysts at Stifel GMP called Valens stock a risk-adjusted opportunity still, and reiterated the Buy rating. Despite this, Stifel still lowered the price target for VLNS from $3.50 to $1.20 which reflects the price of the all-stock takeover. Despite the positive report, shares of VLNS still fell on Tuesday by 1.87% and closed the trading day in Canada at a price of $1.05 CAD per share.
SNDL stock price
In other cannabis news, Tilray (NASDAQ: TLRY) took another step forward in expanding its products and services into Australia and New Zealand. Tilray’s medical division received authorization for clinical studies in the two countries for its Tilray Purified Oral Solution CBD100 line of products. Tilray is one of the largest providers of cannabis and CBD in Australia and New Zealand for both commercial and medical use.
Like this article? Help us with some feedback by answering this survey:
Information on these pages contains forward-looking statements that involve risks and uncertainties. Markets and instruments profiled on this page are for informational purposes only and should not in any way come across as a recommendation to buy or sell in these assets. You should do your own thorough research before making any investment decisions. FXStreet does not in any way guarantee that this information is free from mistakes, errors, or material misstatements. It also does not guarantee that this information is of a timely nature. Investing in Open Markets involves a great deal of risk, including the loss of all or a portion of your investment, as well as emotional distress. All risks, losses and costs associated with investing, including total loss of principal, are your responsibility. The views and opinions expressed in this article are those of the authors and do not necessarily reflect the official policy or position of FXStreet nor its advertisers. The author will not be held responsible for information that is found at the end of links posted on this page.
If not otherwise explicitly mentioned in the body of the article, at the time of writing, the author has no position in any stock mentioned in this article and no business relationship with any company mentioned. The author has not received compensation for writing this article, other than from FXStreet.
FXStreet and the author do not provide personalized recommendations. The author makes no representations as to the accuracy, completeness, or suitability of this information. FXStreet and the author will not be liable for any errors, omissions or any losses, injuries or damages arising from this information and its display or use. Errors and omissions excepted.
The author and FXStreet are not registered investment advisors and nothing in this article is intended to be investment advice.
Recommended content
Editors’ Picks
AUD/USD: The hunt for the 0.7000 hurdle
AUD/USD quickly left behind Wednesday’s strong pullback and rose markedly past the 0.6900 barrier on Thursday, boosted by news of fresh stimulus in China as well as renewed weakness in the US Dollar.
EUR/USD refocuses its attention to 1.1200 and above
Rising appetite for the risk-associated assets, the offered stance in the Greenback and Chinese stimulus all contributed to the resurgence of the upside momentum in EUR/USD, which managed to retest the 1.1190 zone on Thursday.
Gold holding at higher ground at around $2,670
Gold breaks to new high of $2,673 on Thursday. Falling interest rates globally, intensifying geopolitical conflicts and heightened Fed easing bets are the main factors.
Bitcoin displays bullish signals amid supportive macroeconomic developments and growing institutional demand
Bitcoin (BTC) trades slightly up, around $64,000 on Thursday, following a rejection from the upper consolidation level of $64,700 the previous day. BTC’s price has been consolidating between $62,000 and $64,700 for the past week.
RBA widely expected to keep key interest rate unchanged amid persisting price pressures
The Reserve Bank of Australia is likely to continue bucking the trend adopted by major central banks of the dovish policy pivot, opting to maintain the policy for the seventh consecutive meeting on Tuesday.
Five best Forex brokers in 2024
VERIFIED Choosing the best Forex broker in 2024 requires careful consideration of certain essential factors. With the wide array of options available, it is crucial to find a broker that aligns with your trading style, experience level, and financial goals.